Sort by

Send to

Choose Destination

Search results

Items: 2


A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer.

Lindeman GJ, Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Zivanovic Bujak A, Dawson SJ, Gray DHD, Visvader JE.

Cancer Discov. 2018 Dec 5. pii: CD-18-1151. doi: 10.1158/2159-8290.CD-18-1151. [Epub ahead of print]


Spotlight on the utility of the Oncotype DX® breast cancer assay.

Siow ZR, De Boer RH, Lindeman GJ, Mann GB.

Int J Womens Health. 2018 Feb 21;10:89-100. doi: 10.2147/IJWH.S124520. eCollection 2018. Review.

Supplemental Content

Support Center